dc.contributor.author | Abdul-Ghani, Muhammed | |
dc.contributor.author | Williams, Ken | |
dc.contributor.author | Kanat, Mustafa | |
dc.contributor.author | Altuntaş, Yüksel | |
dc.contributor.author | DeFronzo, Ralph Albarado | |
dc.date.accessioned | 10.07.201910:49:13 | |
dc.date.accessioned | 2019-07-10T19:58:01Z | |
dc.date.available | 10.07.201910:49:13 | |
dc.date.available | 2019-07-10T19:58:01Z | |
dc.date.issued | 2013 | en_US |
dc.identifier.citation | Abdul-Ghani, M., Williams, K., Kanat, M., Altuntaş, Y. ve DeFronzo, R. A. (2013). Insulin vs GLP-1 analogues in poorly controlled Type 2 diabetic subjects on oral therapy: A meta-analysis. Journal Of Endocrinological Investigation, 36(3), 168-173. https://dx.doi.org/10.3275/8367 | en_US |
dc.identifier.issn | 0391-4097 | |
dc.identifier.uri | https://dx.doi.org/10.3275/8367 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/3093 | |
dc.description | WOS: 000319889300005 | en_US |
dc.description | PubMed ID: 22522662 | en_US |
dc.description.abstract | To compare insulin and GLP-1 analogues therapy on glycemic control in poorly controlled Type 2 diabetes (T2DM) subjects failing on oral therapy. Methods: The electronic database PubMed was systematically searched for randomized controlled trial (RCT) with duration >16 weeks comparing the addition of insulin therapy vs glucagon-like peptide (GLP-1) analogues in poorly controlled T2DM subjects on oral therapy. Results: We identified 7 RCT with 2199 patients of whom 1119 were assigned to insulin therapy and 1080 received a GLP-1 analogue. Both insulin and GLP-1 analogues were effective in lowering glycated hemoglobin (HbA(1c)) with no statistically significant difference between the mean decreases in HbA(1c). However, insulin was more effective than GLP-1 analogues in lowering the fasting plasma glucose concentration, while GLP-1 agonists were more effective in lowering the postprandial glucose concentration. Insulin therapy was associated with weight gain while GLP-1 analogues consistently caused weight loss and the difference between the mean change in body weight between the two therapies was highly statistically significant. Despite a similar decrease in HbA(1c), the risk of hypoglycemia was 35% lower (p=0.001) with GLP-1 therapy compared to insulin. Compared to insulin, GLP-1 analogues caused a significant decrease in systolic blood pressure and were associated with greater rate of gastrointestinal adverse events. Conclusion/interpretation: In poorly controlled T2DM subjects on oral therapy, GLP-1 analogues and insulin are equally effective in lowering the HbA(1c). However, GLP-1 analogues have additional non-glycemic benefits and lower risk of hypoglycemia. Thus, GLP-1 analogues should be considered as a treatment option in this group of diabetic individuals. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Editrice Kurtis S R L | en_US |
dc.rights | info:eu-repo/semantics/embargoedAccess | en_US |
dc.subject | GLP-1 analogues | en_US |
dc.subject | Insulin | en_US |
dc.subject | Meta-Analysis | en_US |
dc.subject | Type 2 diabetes | en_US |
dc.title | Insulin vs GLP-1 analogues in poorly controlled Type 2 diabetic subjects on oral therapy: A meta-analysis | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Journal Of Endocrinological Investigation | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.identifier.volume | 36 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.startpage | 168 | en_US |
dc.identifier.endpage | 173 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.3275/8367 | en_US |
dc.identifier.wosquality | Q2 | en_US |
dc.identifier.scopusquality | Q2 | en_US |